2021

Serum miRNA Signature in Rheumatoid Arthritis and “At-Risk Individuals”.Cunningham CC, Wade S, Floudas A, Orr C, McGarry T, Wade S, Cregan S, Fearon U, Veale DJ.Front Immunol. 2021 Mar 3;12:633201. doi: 10.3389/fimmu.2021.633201. eCollection 2021.

First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis.

Murray K, Floudas A, Murray C, Fabre A, Crown J, Fearon U, Veale D.

BMJ Case Rep. 2021 Feb 4

COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population

Murray K, Quinn S, Turk M, O’Rourke A, Molloy E, O’Neill L, Mongey AB, Fearon U, Veale DJ.

Rheumatology (Oxford). 2021 Feb 1.

Rheumatoid arthritis CD14 + monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease

McGarry T, Hanlon MM, Marzaioli V, Cunningham CC, Krishna V, Murray K, Hurson C, Gallagher P, Nagpal S, Veale DJ, Fearon U.

Clin Transl Immunology . 2021 Jan 19.

Long-term remission and biologic persistence rates: 12-year real-world data.

Murray K, Turk M, Alammari Y, Young F, Gallagher P, Saber T, Fearon U, Veale DJ.

Arthritis Res Ther. 2021 Jan 13;23(1):25. doi: 10.1186/s13075-020-02380-z.

The PD-1:PD-L1 axis in Inflammatory Arthritis.

Canavan M, Floudas A, Veale DJ, Fearon U.

BMC Rheumatol. 2021 Jan 11;5(1):1. doi: 10.1186/s41927-020-00171-2.